Insurance rules determine who can stay on treatment and who cannot
On the flip side, evening doses might work better for folks who are sensitive to side effects
SUMMIT Trial Study Group, Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V et al (2025) Tirzepatide for heart failure with preserved ejection fraction and obesity
The American Diabetes Association Standards of Care emphasizes the importance of monitoring both efficacy and tolerability of GLP-1 therapies, with follow-up frequency individualized based on the specific medication, titration schedule, and patient response
Collectively, these distinct yet complementary pathways provide a strong mechanistic rationale for the enhanced efficacy of multi-target agonists in treating the multifaceted pathophysiology of MASLD
Safety first: Choose care that prioritizes FDA-regulated medications and evidence-based protocols